

This article was downloaded by:

On: 22 January 2011

Access details: *Access Details: Free Access*

Publisher *Taylor & Francis*

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Journal of Asian Natural Products Research

Publication details, including instructions for authors and subscription information:

<http://www.informaworld.com/smpp/title~content=t713454007>

Triterpenoid prosapogenols and prosapogenins from the husks of *Xanthoceras sorbifolia*

Z.-L. Li^a; X. Li^a; D.-Y. Li^b; D. Li^b; D.-L. Meng^a; W. Li^b; Y. Sha^b

^a Research Department of Natural Medicines, Shenyang Pharmaceutical University, Shenyang, China ^b School of Pharmacy, Shenyang Pharmaceutical University, Shenyang, China

To cite this Article Li, Z.-L. , Li, X. , Li, D.-Y. , Li, D. , Meng, D.-L. , Li, W. and Sha, Y.(2007) 'Triterpenoid prosapogenols and prosapogenins from the husks of *Xanthoceras sorbifolia*', *Journal of Asian Natural Products Research*, 9: 4, 387 – 392

To link to this Article: DOI: 10.1080/10286020600782017

URL: <http://dx.doi.org/10.1080/10286020600782017>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <http://www.informaworld.com/terms-and-conditions-of-access.pdf>

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

Triterpenoid prosapogenols and prosapogenins from the husks of *Xanthoceras sorbifolia*

Z.-L. LI†, X. LI†*, D.-Y. LI‡, D. LI‡, D.-L. MENG†, W. LI‡ and Y. SHA‡

†Research Department of Natural Medicines, Shenyang Pharmaceutical University, Shenyang 110016, China

‡School of Pharmacy, Shenyang Pharmaceutical University, Shenyang 110016, China

(Received 4 January 2006; revised 17 March 2006; in final form 3 April 2006)

Two new prosapogenins, 16-*O*-acetyl-21-*O*-(4-angeloyl)- α -L-rhamnopyranosyl barringtogenol C (**1**), 28-*O*- β -D-glucopyranosyl 16-deoxybarringtogenol C (**2**), were isolated from the acid hydrolyzate of the crude saponin obtained from the husks of *Xanthoceras sorbifolia* Bunge, along with six known triterpenoids. These structures were established on the basis of chemical and detailed spectral evidences. Compounds **1** and **2** showed cytotoxic activity against human cell lines (A375-S2, HeLa).

Keywords: *Xanthoceras sorbifolia*; Sapindaceae; Prosapogenol; Prosapogenin; Cytotoxic activity

1. Introduction

The wood and seeds of *X. sorbifolia* (Sapindaceae) are used as a folk remedy in China to cure rheumatism and enuresis in children [1]. Prior phytochemical studies yielded triterpenoids from the extract of the seeds of the titled plant [2–5]. In our previous work, a saponin and several sapogenols were identified [6,7]. This paper deals with the structural elucidation of two new prosapogenins **1** and **2** obtained in the continued research, and their cytotoxic activities.

2. Results and discussion

Compound **1** was obtained as an amorphous powder. The molecular formula of C₄₃H₆₈O₁₁ was determined by HRESI-MS (m/z 783.4643 [M + Na]⁺) and NMR data. The positive reactions to Liebermann-Burchard and Molish tests characterised it as a triterpene glycoside. The ¹H NMR spectrum displayed the characteristic methyls and olefinic proton signals of olean-12-ene structural moiety, and the signals of H-21, H-22 at δ 4.11, 4.58

*Corresponding author. Email: proflixian@163.com

(each 1H, d, $J = 9.5$ Hz) which were assigned by their correlations with the adjacent carbons in the HMBC spectrum. Additionally, the signals of an acetyl group at δ 2.20 (3H, s) and those of an angeloyl functionality at δ 5.84 (1H, m), 1.88 (3H, br. s) and 1.95 (3H, d, $J = 7.3$ Hz), along with an anomeric proton appearing at δ 5.46 (1H, br. s) and a methyl doublet at δ 1.35 (3H, d, $J = 6.3$ Hz) ascribable to a 6-deoxy hexose were observed. The ^{13}C NMR spectrum showed the signals according to the acetyl and angeloyl moieties above, together with six carbons of the sugar moiety at δ 104.3, 72.6, 72.0, 75.1, 68.2 and 18.1 assigned to rhamnose which was also detected on acid hydrolysis of **1**. The α -anomeric configuration of the sugar was ascertained based on its diagnostic C-5 signal at δ 68.2 [8]. Furthermore, 30 typical carbon signals in agreement with those of barringtonol C (**3**), except for the remarkable downfield shifts of C-16 and C-21 were discerned.

The NMR data were assigned appropriately by the HSQC and HMBC experiments. In the HMBC spectrum, crosspeaks observed between H-1 of Rha at δ 5.46 and C-21 at δ 89.9, together with the long-range correlation between H-16 at δ 5.92 and the carbon at δ 169.7 (—OCOME) suggested the rhamnose and acetyl moiety were located at C-21 and C-16, respectively. In addition, the correlation between H-4 of Rha at δ 5.84 and carbon at δ 168.0 (angeloyl C-1) defined the position of angeloyl group at C-4 (δ 75.1) of the rhamnose moiety. Consequently, compound **1** was identified as 16-*O*-acetyl-21-*O*-(4-*O*-angeloyl)- α -L-rhamnopyranosyl barringtonol C (figure 1).

Compound **2**, positive to the Molish test, was obtained as white needles and assigned a molecular formula of $\text{C}_{36}\text{H}_{60}\text{O}_9$ established by HRESI-MS (m/z 659.4127 $[\text{M} + \text{Na}]^+$) and NMR data. ^1H NMR spectrum showed the signals of the aglycone similar to those of compound **4** (16-deoxybarringtonol C) [9], except for the broad singlet at δ 4.16 (2H, br. s) instead of the AB coupling system in H-28 of **4** at δ 4.16, 3.81 (each 1H, d, $J = 10.3$ Hz). Moreover, an anomeric proton of the sugar moiety at δ 4.99 (1H, d, $J = 7.8$ Hz) was also observed. Among the 36 carbon signals in the ^{13}C NMR spectrum, 30 signals were assigned to the aglycone. The other six carbon signals at δ 105.5, 75.2, 78.7, 71.7, 78.5, and 62.8, combined with the result of the acid hydrolysis of **2**, were indicative of the presence of a glucose, whose β -anomeric configuration was determined by its large $J_{\text{H1-H2}}$ value of 7.8 Hz.




Figure 1. Structure and key HMBC correlations of **1**.




Figure 2. Structure and key HMBC correlations of **2**.

In the HMBC experiment, the proton signal at δ 4.16 was designated to the methylene at C-28 on the basis of its correlations with carbons at δ 18.5 (C-16), 42.2 (C-18), and 74.8 (C-22). Accordingly, the carbon signal at δ 74.4 was designated to C-28 by the HSQC experiment. Further analysis of the HMBC spectrum showed the correlation between the anomeric proton (δ 4.99) and C-28, which confirmed the attachment of the sugar moiety. Based on the observations above, compound **2** was characterised as 28-*O*- β -D-glucopyranosyl 16-deoxybarringtonenol C (figure 2).

Compounds **1–8** were tested for the cytotoxic activities *in vitro* against human tumour cell lines (A375-S2, HeLa), among which **1–6** showed activity with IC_{50} values from 15.1 to 74.5 μ mol/L, compounds **7** and **8** were nearly inactive (see table 2). Therefore, the structure–activity relationship could be established as that the glycosidation at C-21 played positive role in the cytotoxic activity, while the hydroxy groups at C-15 or -16, and the sugar moieties attached to C-28 were negative to the activity.

3. Experimental

3.1 General experimental procedures

Melting points were determined on a Yanaco MP-S₃ apparatus and are uncorrected. ESI-MS were performed on an Agilent 1100 ion trap spectrometer. HRESI-MS were taken on QSTAR LCQ mass spectrometer. Optical rotations were measured with a Perkin–Elmer 241 polarimeter. NMR spectra were taken on a Bruker-ARX-300 or Bruker-AV-600 spectrometer, using TMS as an internal standard. Macroporus resin (HPD-100) was produced by Cangzhou Bon Chemical Co. Ltd, P.R. China.

3.2 Plant material

The plant material was collected from Shenyang, Liaoning Province, China, in October 1997 and identified by Associate Professor Bai-Zhen Yang. A voucher specimen (No. 0154620) is

deposited in the Herbarium Department of the Institute of Applied Ecology, Chinese Academy of Sciences.

3.3 Extraction and isolation

The crushed husks of *X. sorbifolia* Bunge (15.0 kg) were extracted with 70% aqueous EtOH (120 L \times 3). After evaporation of the solvent *in vacuo*, the extract was suspended in H₂O and partitioned with CHCl₃ (5 L \times 3) and n-BuOH (5 L \times 5), successively. A part of the n-BuOH extract (40.0 g), was dissolved in water (200 ml) and subjected to column chromatography on macroporus resin (HPD-100, 400 g), eluted with H₂O (1500 ml), 70% aqueous EtOH (1500 ml) and EtOH (1500 ml) successively. Evaporation of the 70% EtOH eluate *in vacuo* gave the crude saponin as pale powder (20.0 g).

A solution of crude saponin (3.0 g) in 1 M HCl/EtOH (1:1, 150 ml) was refluxed for 2 h. The reaction mixture was diluted with 50 ml of H₂O and concentrated to 100 ml to afford a brown precipitate, which was washed with H₂O to yield a mixture of saponins and prosapogenins (600 mg).

The mixture (500 mg) was chromatographed on silica gel (10.0 g) eluted in a stepwise manner with petroleum ether (PE, 60–90°C)/EtOAc/acetone (from 15:1:1 to 1:1:1, 100 ml each) to give **5** (11:1:1, 10 mg) and **8** (9:1:1, 150 mg). The subfraction (5:1:1, 180 mg) was further subjected to column chromatography on silica gel (5.0 g) eluted with CHCl₃/MeOH to afford **6** (100:1, 25 ml, 15 mg), **1** (100:2, 25 ml, 20 mg) and **4** (100:4, 50 ml, 30 mg). Rechromatography of the subfraction (1:1:1, 70 mg) on silica gel (5.0 g) with CHCl₃/MeOH (100:10) as the elution led to the isolation of **3** (25 ml, 15 mg), **7** (50 ml, 9 mg) and **2** (200 ml, 25 mg).

3.3.1 Compound 1. White amorphous powder, mp 230–232°C. $[\alpha]_D^{20} - 15$ (c 0.10, MeOH). HRESI-MS m/z 783.4643 [M + Na]⁺ (calcd for C₄₃H₆₈O₁₁Na, 783.4659). Positive ESI-MS: $m/z = 783.5$ [M + Na]⁺, 723.4 [M + Na-AcOH]⁺, 495.1 [M + Na-AcOH-angeloxyl-Rha]⁺; negative ESI-MS: $m/z = 795.9$ [M + Cl]⁻; DEPT, ¹H NMR and ¹³C NMR data: see table 1.

3.3.2 Compound 2. White needles (MeOH), mp 272–274°C. $[\alpha]_D^{20} - 22$ (c 0.10, MeOH/H₂O 1:1). HRESI-MS m/z 659.4127 [M + Na]⁺ (calcd for C₃₆H₆₀O₉Na, 659.4135). Positive ESI-MS: $m/z = 659.4$ [M + Na]⁺, 258.2; negative ESI-MS: $m/z = 671.2$ [M + Cl]⁻; DEPT, ¹H NMR and ¹³C NMR data: see table 1.

The known compounds barringtonenol C (**3**), 16-deoxybarringtonenol C (**4**), 21,22-di-*O*-angeloyl barringtonenol C (**5**), 21-*O*-(3,4-di-*O*-angeloyl)- β -D-fucopyranosyl barringtonenol C (**6**), R₁-barrigenol (**7**), 21,22-di-*O*-angeloyl R₁-barrigenol (**8**), were identified by comparison of the physical and NMR data with those reported in the literature [2,4,9–11].

3.4 Cytotoxic activity assay

The MTT method was used as described [12] with six concentration levels (10, 20, 50, 60, 80, 100 μ mol/L). Taxol was added paralleling with the tested compounds as the reference. Cell growth was measured by MTT with a plate reader. The percentage of cell inhibition was calculated as follows: Cell death (%) = $[A_{490}(\text{control}) - A_{490}(\text{test})]/A_{490}(\text{control}) \times 100\%$. IC₅₀ values were calculated with the LOGIT method.

Table 1. ^1H NMR, ^{13}C NMR and DEPT (135°) spectral data of **1** and **2** (δ value, in $\text{C}_5\text{D}_5\text{N}$).

1			2		
Position	^1H (J Hz)	^{13}C	Position	^1H (J Hz)	^{13}C
1	1.00, 1.54	39.1t	1	1.00, 1.58	39.1t
2	1.50, 1.82	28.1t	2	1.82, 1.87	28.1t
3	3.40 (dd, 11.0, 5.0)	78.0d	3	3.43 (dd, 11.1, 4.7)	78.5d
4		39.4s	4		39.4s
5	0.80	55.8d	5	0.85 (d, 11.5)	55.8d
6	1.37, 1.57	18.7t	6	1.38, 1.54	18.8t
7	1.15, 1.40	33.2t	7	1.25, 1.51	32.9t
8		39.7s	8		40.2s
9	1.68	47.1d	9	1.65 (t, 8.8)	48.0d
10		37.2s	10		37.2s
11	1.80, 1.87	23.9t	11	1.86, 1.90	23.9t
12	5.47 br s	124.5d	12	5.34 br s	123.4d
13		141.9s	13		143.5s
14		41.4s	14		41.9s
15	1.66, 1.90	31.1t	15	1.05, 1.86	25.8t
16	5.92 br s	71.8d	16	1.96	18.5t
				2.27 (d, 13.5)	
17		47.8s	17		43.7s
18	2.89 (d, 13.6)	40.1d	18	2.66 (d, 13.6)	42.2d
19	1.34	47.3t	19	1.31 (dd, 13.6, 4.6)	46.7t
	2.55 (t, 13.6)			2.13 (t, 13.6)	
20		37.1s	20		36.3s
21	4.11 (d, 9.5)	89.9d	21	3.79 (d, 9.9)	76.9d
22	4.58 (d, 9.5)	70.4d	22	4.44 (d, 9.9)	74.8d
23	1.23	28.7q	23	1.24	28.8q
24	1.03	16.6q	24	1.05	16.6q
25	0.90	16.0q	25	0.98	15.8q
26	0.82	16.9q	26	0.92	17.1q
27	1.45	27.1q	27	1.26	26.3q
28	3.62, 3.92 (d, 10.2)	65.1t	28	4.16 br s	74.4t
29	1.11	30.6q	29	1.25	30.4q
30	1.19	19.9q	30	1.22	19.3q
16-acyl			28-sugar		
1'		169.7s	1'	4.99 (d, 7.8)	105.5d
2'	2.20	22.1q	2'	4.05 (t, 7.8)	75.2d
21-sugar			3'	4.19 (dd, 9.0, 7.8)	78.7d
1''	5.46 br s	104.3d	4'	4.24 (dd, 9.0, 8.0)	71.7d
2''	4.68 br s	72.6d	5'	3.95 m	78.5d
3''	4.58 (d, 9.5)	72.0d	6'	4.42 (dd, 11.4, 4.8)	62.8t
				4.53 (d, 11.4)	
4''	5.84	75.1d			
5''	4.74 (dd, 9.5, 6.3)	68.2d			
6''	1.35 (d, 6.3)	18.1q			
4''-acyl					
1'''		168.0s			
2'''		128.7s			
3'''	5.84	137.3d			
4'''	1.95 (d, 7.3)	15.8q			
5'''	1.88	20.9q			

Table 2. Inhibition on tumour cell lines of compounds **1–8** (IC_{50} , $\mu\text{mol/L}$).

	1	2	3	4	5	6	7	8	Taxol
A375-S2	25.0	70.3	74.4	52.4	70.3	34.1	>100	>100	39.5
HeLa	15.1	74.5	>100	49.4	>100	63.7	>100	>100	15.4

References

- [1] Jiangsu New Medical College, *Dictionary of Chinese Herb Medicine*, p. 496, Shanghai Press of Science and Technology, Shanghai (1986).
- [2] Y.J. Chen, T. Takeda, Y. Ogihara, Y. Iitaka. *Chem. Pharm. Bull.*, **32**, 3378 (1984).
- [3] Y.J. Chen, T. Takeda, Y. Ogihara, Y. Iitaka. *Chem. Pharm. Bull.*, **33**, 127 (1985).
- [4] Y.J. Chen, T. Takeda, Y. Ogihara, Y. Iitaka. *Chem. Pharm. Bull.*, **33**, 1043 (1985).
- [5] Y.J. Chen, T. Takeda, Y. Ogihara, Y. Iitaka. *Chem. Pharm. Bull.*, **33**, 1387 (1985).
- [6] Z.L. Li, X. Li, L.H. Li, N. Li, M. Yu, D.L. Meng. *Planta Med.*, **71**, 1068 (2005).
- [7] Z.L. Li, B.Z. Yang, X. Li, S.J. Wang, N. Li, Y. Wang. *J. Asian Nat. Prod. Res.*, **8**, 361 (2006).
- [8] S.M. Sang, A. Lao, H.C. Wang, Z.L. Chen. *Phytochemistry*, **52**, 1611 (1999).
- [9] P.W. Khong, K.G. Lewis. *Aust. J. Chem.*, **33**, 1311 (1977).
- [10] M.D. Greca, A. Fiorentino, P. Monaco, L. Previtiera. *Phytochemistry*, **35**, 201 (1994).
- [11] E. Aurada, J. Jurenitsch, W. Kubelka. *Planta Med.*, **50**, 391 (1984).
- [12] Y. Zhang, L.J. Wu, S. Tashiro, S. Onodera, T. Ikejima. *Acta. Pharmacol. Sin.*, **25**, 83 (2004).